Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?
+ Author Affiliations
- Corresponding Author:
Frédéric Bost, INSERM U895, Bât. Archimed, 151 route de St Antoine de Ginestière BP 2 3194, 06204 NICE Cedex 3 France. Phone: 33-489064229; Fax: 33-489064221. E-mail: bost@unice.fr
Abstract
Metformin is the most widely used
antidiabetic drug in the world, and there is increasing evidence of a
potential efficacy
of this agent as an anticancer drug. First,
epidemiological studies show a decrease in cancer incidence in
metformin-treated
patients. Second, metformin decreases insulin
resistance and indirectly reduces insulin level, a beneficial effect
because
insulin promotes cancer cell growth. Third, several
reports outline a direct inhibitory effect of metformin on cancer cell
growth and an antitumoral action. Finally,
metformin activates the AMP activated protein kinase (AMPK) pathway, a
major sensor
of the energetic status of the cell, which has been
proposed as a promising therapeutic target in cancer. Mol Cancer Ther;
9(5); 1092–99. ©2010 AACR.
Footnotes
- Received December 18, 2009.
- Revision received March 8, 2010.
- Accepted March 12, 2010.
- ©2010 American Association for Cancer Research.
CiteULike
Connotea
Delicious
Digg
Facebook
Reddit
Technorati
Twitter
Articles citing this article
-
Posted:
$225 to $300 for 90 minutes Market Research Cancer Study (NYC and surrounding areas)
$225 to $300 for 90 minutes Market Research Cancer Study (Surrounding Area of NY city)
Tuesday, March 11th, 2014
• Topic: Oncology: NSCLC (Lung cancer patients; NSCLC (Lung cancer caregivers; ); Melanoma (form of skin cancer patients)
Length: 90 min Triads and Dyads
Incentives: $300 -- Visa Gift Card -- Patients
$225 -- Visa Gift Card -- Caregivers
$75 -- Visa Gift Card -- Transportation if necessary (can be used for cab, or an incentive for another person who drives the patient to the interview (but does not participate in the caregiver research)
$50 -- Visa Gift Card- Referral - per qualified referred participant who attends session.
We are a market research company and you could look us up on-line and via FB and LinkedIN. Different patients sometimes respond in different ways to the same medicine, and some side effects may not be discovered until many people have used a medicine over a period of time. For this reason, we are conducting a study for a manufacturer of medicines and provide them with details of any side effects related to their own products that are mentioned during the course of market research. I look forward to receiving a response from you. It is a great opportunity for patients living with these two types of cancer to contribute to improving the medications to further help them as well as future patients. Of course it will on a volunteer basis and would like for you to be able to share this with your members/patients
Although what patients say will, of course, be treated in confidence, should the patient mention during the discussion a side effect that s(he) or someone they know, became ill after taking one of the medicines, we will need to report this, so that our client can learn more about the safety of its medicines. Adverse experience information provided is shared with regulatory agencies, the sponsoring company's subsidiaries worldwide, and business partners with whom the sponsoring company has contractual agreements. Any information that identifies the patient directly, such as the patient's initials or date of birth, will be handled confidentially. Their responses will be otherwise confidential and will not be used for any other purposes or disclosed to any third party without their approval.
Patients and caregivers must show proof of condition and caregivers who are caring for family member who is a patient.
Please respond:
Name
Age
Type of cancer
Cell
Ethnicity
No comments:
Post a Comment